2-甲基-2-丙基4-[(3-氟苯基)氨基]-1-哌啶羧酸酯 | 679409-18-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-甲基-2-丙基4-[(3-氟苯基)氨基]-1-哌啶羧酸酯
• 中文别名: 4-((3-氟苯基)氨基)哌啶-1-羧酸叔丁酯
• 英文名称: tert-butyl 4-((3-fluorophenyl)amino)piperidine-1-carboxylate
• 英文别名: tert-butyl 4-(3-fluorophenylamino)piperidine-1-carboxylate；1,1-dimethylethyl 4-((3-fluorophenyl)amino)-1-piperidinecarboxylate；1,1-dimethylethyl 4-[(3-fluorophenyl)amino]-1-piperidinecarboxylate；tert-butyl 4-[(3-fluorophenyl)amino]piperidine-1-carboxylate；tert-butyl 4-(3-fluoroanilino)-1-piperidinecarboxylate；tert-butyl 4-(3-fluoroanilino)piperidine-1-carboxylate
• CAS: 679409-18-8
• 化学式: C₁₆H₂₃FN₂O₂
• 分子量: 294.369
• InChiKey: ZJWJLMVMSWQJEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 储存条件：
  2-8℃

反应信息

• 作为反应物：
  描述：

  2-甲基-2-丙基4-[(3-氟苯基)氨基]-1-哌啶羧酸酯 在 sodium hydride 、 三氟乙酸 作用下， 以 二氯甲烷 、 mineral oil 为溶剂， 反应 6.25h， 生成 N-(3-fluorophenyl)-2-phenoxy-N-(piperidin-4-yl)acetamide
  参考文献：
  名称：

  1,4-二取代哌啶衍生物的合成及抗疟活性

  摘要：

  为了以低成本制备对恶性疟原虫有活性且副作用较小的新化合物，我们设计并合成了 4-氨基哌啶衍生物 6 的 1,4-二取代哌啶衍生物库。已针对恶性疟原虫的氯喹敏感 (3D7) 和氯喹抗性 (W2) 菌株进行了评估。最活跃的分子 - 化合物 12d (13.64 nM (3D7))、13b (4.19 nM (3D7) 和 13.30 nM (W2)) 和 12a (11.6 nM (W2)) - 与氯喹 (22.38 nM (3D7)) 相当和 134.12 nM (W2))。

  DOI：

  10.3390/molecules25020299
• 作为产物：
  描述：

  在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 2-甲基-2-丙基4-[(3-氟苯基)氨基]-1-哌啶羧酸酯
  参考文献：
  名称：

  The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor

  摘要：

  Optimisation of urea (5), identified from high throughput screening and subsequent array chemistry, has resulted in the identification of pyridine carboxamide (33) which is a potent motilin receptor agonist possessing favourable physicochemical and ADME profiles. Compound (33) has demonstrated prokinetic-like activity both in vitro and in vivo in the rabbit and therefore represents a promising novel small molecule motilin receptor agonist for further evaluation as a gastroprokinetic agent. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.072

文献信息

• [EN] CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS<br/>[FR] ANTAGONISTES DE CCR5 EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009058924A1

  公开（公告）日：2009-05-07

  The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及用于治疗CCR5相关疾病和障碍的化合物，例如，可用于抑制HIV复制，预防或治疗HIV感染，以及治疗由此导致的获得性免疫缺陷综合症（艾滋病）。
• [EN] CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS<br/>[FR] ANTAGONISTES DE CCR5 COMME AGENTS THÉRAPEUTIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009075960A1

  公开（公告）日：2009-06-18

  The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及在治疗与CCR5相关的疾病和紊乱中有用的化合物，例如，在抑制HIV复制、预防或治疗HIV感染以及治疗由此导致的获得性免疫缺陷综合症（AIDS）方面有用的化合物。
• [EN] NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AZOTÉS ET LEUR APPLICATION DANS DES MÉDICAMENTS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015090232A1

  公开（公告）日：2015-06-25

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法以及作为药物的用途，特别是用于治疗和预防组织纤维化。本文还提供了包含这些含氮杂环化合物的药用可接受组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、IPF、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• [EN] 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS<br/>[FR] DERIVES DE 4-AMINOPIPERIDINE, PROCEDES DE PREPARATION DE CES DERIVES ET UTILISATION DE CES DERIVES COMME MEDICAMENTS
  申请人：UCB SA

  公开号：WO2004030668A1

  公开（公告）日：2004-04-15

  The present invention relates to 4-aminopiperidine derivatives, to processes for their preparation, to their use in therapy and to pharmaceutical compositions containing them. More particularly these compounds are useful for treatment of disorders of the central and/or peripheral nervous system. Of particular interest, is the potent antidepressant activity shown by these compounds.

  本发明涉及4-氨基哌啶衍生物，涉及它们的制备工艺，涉及它们在治疗中的应用，以及含有它们的药物组合物。更具体地说，这些化合物对中枢和/或外周神经系统疾病的治疗非常有用。特别值得关注的是这些化合物所展示的强效抗抑郁活性。
• 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments
  申请人：Lamberty Yves

  公开号：US20060128753A1

  公开（公告）日：2006-06-15

  The present invention relates to 4-aminopiperidine derivatives, to processes for their preparation, to their use in therapy and to pharmaceutical compositions containing them. More particularly these compounds are useful for treatment of disorders of the central and/or peripheral nervous system. Of particular interest, is the potent antidepressant activity shown by these compounds.

  本发明涉及4-氨基哌啶衍生物，其制备方法，其在治疗中的应用以及含有它们的制药组合物。更具体地说，这些化合物对于治疗中枢和/或外周神经系统疾病非常有用。特别值得注意的是，这些化合物表现出的强效抗抑郁活性。